Purchase this article with an account.
R.J. Noecker; Evaluation of Bimatoprost 0.03% versus Latanoprost 0.005%: A Paired Comparison Study . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2452.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Evaluate the IOP–lowering efficacy of bimatoprost 0.03% and latanoprost 0.005%, using each patient as their own control. Methods: Multi–center, randomized, investigator–masked, paired–comparison trial. Patients (n=83) with bilateral glaucoma or ocular hypertension, an untreated IOP between 22–34 mm Hg, and no more than a 2 mm Hg between eye difference in IOP were randomized to use bimatoprost in one eye and latanoprost in the other for 2 months. Study visits were at baseline and months 1 and 2. Results: Baseline IOP was similar between latanoprost and bimatoprost treated eyes (24.2 vs. 24.3 mmHg, P=.510). At month 1, the mean IOP reduction from baseline was 7.7 mm Hg (31.5%) in bimatoprost–treated eyes, compared with 6.4 mm Hg (26.4%) in the latanoprost–treated eyes (difference of 1.3 mm Hg, P<.001). At month 2, the mean IOP reduction from baseline was 7.0 mm Hg (28.5%) in the bimatoprost–treated eyes and 5.7 mm Hg (23.4%) in the latanoprost–treated eyes (difference of 1.3 mm Hg, P<.001). The most common adverse event with both medications was conjunctival hyperemia (25% in bimatoprost and 15% in latanoprost–treated eyes.) Conclusions: These data support previous studies indicating that bimatoprost provides greater IOP lowering than latanoprost. This is the first study demonstrating that bimatoprost provides greater IOP lowering than latanoprost when comparing different eyes of the same patient.
This PDF is available to Subscribers Only